Atea Pharmaceuticals Inc. (AVIR) is advancing late-stage antiviral programs, led by its Phase 3 hepatitis C trials of Bemnifosbuvir and Ruzasvir. With enrollment completed in the pivotal C-BEYOND study and topline results expected in 2026, the company is positioning itself to deliver shorter, more tolerable treatment options.
Backed by a solid cash position and a growing pipeline that now includes hepatitis E candidates, Atea continues to attract market attention ahead of critical trial data.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com